Motorsport Games The Trade: Motorsport Games Inc.(NASDAQ:MSGM) 10% owner Mike Zoi acquired a total of 338,983 shares at an average price of $2.95. The insider spent $1 million to buy those shares. What's Happening: Motorsport Games, last month, entered into equity purchase agreement. What Motorsport Games Does: Motorsport Games Inc is a motorsport network company that combines engaging video games with esports competitions and content for racing fans and gamers around the globe. _____________________ Short at $8 Stoney!!
Hi Van- Be careful with MSGM. It's a wild one. We had it pegged for along time but it went down down down. Then they did some sort of reverse merge I think-- suddenly the price came up. I agree this s a $3 stk! But easy to manipulate. Deff not something i would recommend to others- For that... May i welcome you to <<< GBA CHINA APPRECIATION DAY!!!! >>> STARRING YOUR FAVORITE EV CAR MAKER-- NIO.
Well kiddos we are in that place I warned about a few weeks ago. Always first to spot these inflection points in the market aren't I? It's a gift. And a curse. Apple holds the key to the future of the market. Apple has the ability to confirm the sell off or halt it.
Apple is one leg of the stool, the Fed the other and the third leg? It's The Debt ceiling talk with the new hardened Republicans<--- I first warned about this months ago well now it's happening. These combined factors are why we are so wobbly now-- that and some pretty average earnings but not terrible<-----
On NIO I gave some option choices yesterday. Did you take a peek.? I will probably buy the straight stock because this is a stock forum and the Option King only comes around when he is pretty, pretty sure-- and that's Expedia<---- So if you can help--> EXPD option is what we are looking for with maybe a minor play on NIO. I'm going to get you an up 13% or $1 + sort of day on NIO (maybe more this week). I see NIO above $13. Although many are betting against me-!
Yeah. The biggest week in earmings, an FOMC decision, and several economic reports. ONLY STONEY SAW THIS WEEK COMING.
Natura &Co upgraded to Buy from Neutral at BofA <----- STOCK OF THE DAY-- NTRA Natera, Inc.(NTRA) We’ll start with Natera, a biotech company operating in the cell-free DNA testing niche, or cfDNA. cfDNA tests are minimally invasive, based on a simple blood draw, and focus on naturally occurring DNA fragments that float freely in the bloodstream. Natera’s technology captures those fragments and uses them for genetic testing. The company’s testing platforms are based on novel molecular biology techniques and AI driven bioinformatics software, and can detect single DNA molecules in a blood sample tube. Natera uses this technology for accurate, non-invasive prenatal testing (the Panorama platform), tumor-specific assay testing for individualized cancer treatments (the Signatera platform), and best-in-class rejection assessment testing prior to kidney transplantation (the Prospera platform). Diagnostic DNA testing is big business, and Natera is capitalizing on patients’ desire for a less invasive medical experience. The company’s revenues have been showing steady growth for the past several years, and in the last reported quarter, 3Q22, Natera saw a top line of $210.6 million, up 33% year-over-year. The revenue gain came on top of a 27% increase in processed tests during 3Q22, from 407,300 to 517,500. Of that total, the oncology segment saw the strongest growth; the company processed 53,000 oncology tests in the quarter, for a 153% y/y increase. Natera revised its forward guidance upward in the Q3 report, projecting full-year 2022 revenue of $810 million to $830 million. This was up $40 million at the midline from the previously published guidance. The company is expected to report the 4Q22 results late in February, and we’ll find out then how the guidance holds up. Joining the bulls, Raymond James' Andrew Cooper takes an upbeat stance on this company and its stock. "With each of its segments growing nicely in the near- and intermediate-terms and a catalyst rich setup in 2023, particularly in oncology, we are upgrading shares to Outperform. Leadership in the burgeoning MRD space, where we think it can win additional coverage and potentially guideline inclusion at least for CRC, generates the excitement, while an increasingly profitable women’s health business has its own catalysts in conversation around 22q. This all comes at a valuation that looks, at least on a relative basis, reasonably accommodative all things considered," the analyst opined. Cooper's Outperform (i.e. Buy) rating on NTRA comes with a $58 price target, which implies a one-year upside potential of 35%. Overall, this interesting biotech has picked up 9 recent analyst reviews, including 8 Buys against a single Hold – for a Strong Buy consensus rating. The shares are trading for $42.94 and their average price target, at $63,